Cingulate Inc.

NasdaqCM CING

Cingulate Inc. Market Capitalization on January 14, 2025: USD 14.84 M

Cingulate Inc. Market Capitalization is USD 14.84 M on January 14, 2025, a -73.97% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Cingulate Inc. 52-week high Market Capitalization is USD 57.02 M on January 16, 2024, which is 284.22% above the current Market Capitalization.
Cingulate Inc. 52-week low Market Capitalization is USD 4.09 M on June 28, 2024, which is -72.41% below the current Market Capitalization.
Cingulate Inc. average Market Capitalization for the last 52 weeks is USD 14.88 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: CING

Cingulate Inc.

CEO	Dr. Shane J. Schaffer Pharm.D.
IPO Date	Dec. 8, 2021
Location	United States
Headquarters	1901 West 47th Place
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Key trends

Past 5 years